MedTrace Logo

Expanded Access [11C] Methionine PET Imaging

NCT05511714 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-04-24

No results posted yet for this study

Summary

The participants are being asked to get this PET scan because the participants have or may have cancer in the central nervous system (head, neck, or spine), and the investigator and the patient's physician thinks that this scan may provide useful information for the participant's treatment.

Primary Objective

To provide expanded access to L-\[11C\]methionine as a positron-emitting tracer in children and young adults for the positron emission tomography (PET) imaging of neoplasms of the central nervous system (CNS) and head and neck to guide therapeutic management of disease.

Conditions

  • Central Nervous System Tumor
  • Head and Neck Neoplasms

Interventions

DRUG

L-(11C) methionine

Injected intravenously with 20 mCi/1.7 sq m body surface area of L-\[methyl-11C\]methionine (maximum prescribed dose: 20 mCi).

Sponsors & Collaborators

Principal Investigators

  • Barry L. Shulkin, MD, MBA · St. Jude Children's Research Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05511714 on ClinicalTrials.gov